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OBJECTIVE: Obstructive sleep apnea is common among patients with hypertrophic cardiomyopathy and may
contribute to poor cardiovascular outcomes. However, obstructive sleep apnea is largely unrecognized in this
population. We sought to identify the clinical predictors of obstructive sleep apnea among patients with
hypertrophic cardiomyopathy.
METHODS: Consecutive patients with hypertrophic cardiomyopathy were recruited from a tertiary University
Hospital and were evaluated using validated sleep questionnaires (Berlin and Epworth) and overnight portable
monitoring. Ninety patients (males, 51%; age, 46¡15 years; body mass index, 26.6¡4.9 kg/m2) were included,
and obstructive sleep apnea (respiratory disturbance index $15 events/h) was present in 37 patients (41%).
RESULTS: Compared with the patients without obstructive sleep apnea, patients with obstructive sleep apnea
were older and had higher body mass index, larger waist circumference, larger neck circumference, and higher
prevalence of atrial fibrillation. Excessive daytime sleepiness (Epworth scale) was low and similar in the patients
with and without obstructive sleep apnea, respectively. The only predictors of obstructive sleep apnea (using a
logistic regression analysis) were age $45 years (odds ratio [OR], 4.46; 95% confidence interval [CI 95%], 1.47–
13.54; p=0.008) and the presence of atrial fibrillation [OR, 5.37; CI 95%, 1.43–20.12; p=0.013].
CONCLUSION: Consistent clinical predictors of obstructive sleep apnea are lacking for patients with
hypertrophic cardiomyopathy, which suggests that objective sleep evaluations should be considered in this
population, particularly among elderly patients with atrial fibrillation.
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& INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is a common genetic
cardiac disease that is characterized by left ventricular (LV)
hypertrophy associated with non-dilated ventricular chambers
in the absence of another cardiac or systemic disease capable of
producing this hypertrophy (1). HCM is a potentially devastat-
ing disease; it occurs in all age groups (1) and is a significant
cause of disability, including heart failure, atrial fibrillation
(AF), and sudden death (2). Despite all efforts, the sudden death
rate in HCM patients is approximately 1% per year, and this
disease primarily affects patients older than 55 years (3–5).
Obstructive sleep apnea (OSA) is characterized by
recurrent episodes of either partial or complete upper
airway obstruction during sleep, leading to fragmented
sleep and intermittent hypoxia (6). Growing evidence shows
that OSA triggers a cascade of deleterious effects to the
cardiovascular system, including increased sympathetic
activity, oxidative stress, systemic inflammation, insulin
resistance, endothelial dysfunction, atherosclerosis, and
heart remodeling (7,8). OSA is considered to be a risk factor
for hypertension and is independently associated with poor
cardiovascular outcomes in the general population (9,10).
The typical features of OSA patients who are referred to
sleep laboratories include male, obese, loud snoring, and
symptoms of excessive daytime sleepiness.
Novel evidence shows that OSA is surprisingly common
among patients with HCM, with prevalences ranging from
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32% to 71%, depending on the diagnostic criteria (11–15).
Because HCM is commonly diagnosed at young ages, the
presence of OSA among HCM patients has been largely
ignored. Moreover, for reasons that are not completely
understood, evidence indicates that the patients with HCM
and OSA are typically less obese than the patients with
OSA observed in sleep clinics (13,15). However, cross-
sectional data suggest that similarly to what has been well
established in other populations, the presence of OSA may
contribute to poor cardiovascular outcomes in HCM
patients (16). For instance, in HCM patients, OSA has been
independently associated with left atrial enlargement and
AF (13,14), which is a risk factor for sudden death in these
patients.
We have previously reported a high prevalence of OSA
among HCM patients (13). Though the previous study
conveyed novel and important findings, the clinical char-
acteristics and predictors of OSA were not described.
Therefore, the objective of the present study was to identify
the predictors of OSA that may help to increase the
awareness and diagnosis of OSA in HCM patients.
& METHODS
Study design
This cross-sectional observational study evaluated con-
secutive HCM patients who were previously diagnosed
according to the standard criteria described below. All
patients were recruited from the Cardiomyopathy Clinical
Unit, (Clinical Unit of Cardiomyopathies) at the Heart
Institute (InCor), University of Sa˜o Paulo School of
Medicine, Sa˜o Paulo, Brazil, between March 2008 and
October 2011. Each patient had been diagnosed with HCM
with asymmetric septal hypertrophy, with septal thickness
$15 mm in the absence of other known causes of left
ventricular hypertrophy, such as hypertension and aortic
stenosis (17). We included patients of both genders who
were older than 18 years. Patients with another cardiac
diseases and clinical instability, as defined by a recent
hospital admission (the previous 6 months), were excluded.
Clinical evaluation
All HCM patients underwent a detailed history and
physical examination, including anthropometric and clinical
data. We used two questionnaires, the Berlin questionnaire
and the Epworth Sleepiness Scale, to evaluate the risk of
having OSA and the level of excessive daytime sleepiness,
respectively, as described below:
Berlin Questionnaire - This questionnaire classifies
patients at low and high risk for OSA based on responses
in three symptom categories regarding: 1) snoring, 2)
tiredness, and 3) the presence of obesity (BMI $30 kg/m2)
or hypertension. Patients positive for at least two symptom
categories were considered at high risk for OSA (18).
Because none of the patients with HCM had hypertension,
the third domain of the Berlin questionnaire was restricted
to obesity.
Epworth Sleepiness Scale (ESS) - The ESS is used to
evaluate subjective excessive daytime sleepiness. Briefly, the
patient rates the probability of dozing (0 to 3) in eight
different situations. A score above 10 is considered positive
for the presence of excessive daytime sleepiness (19).
Sleeps study
All participants underwent an overnight study with a
standard 4-channel recording device (Stardust II,
Respironics Inc., Murrysville, Pennsylvania, USA). This
device records nasal pressure, thoracic excursion (as
measured using a piezoelectric crystal), body position,
pulse oxymetry, and heart rate. The device is classified as
a type 3 monitor in accordance with the AASM recommen-
dations (20). The portable monitoring sleep study was
unattended and performed at home. Hypopnea was defined
as a $50% discernible decrement in airflow lasting $10 s
with a 3% reduction in oxygen saturation. Apnea was
defined when cessation of airflow lasted $10 s and was
further classified as central, obstructive, or mixed based on
the presence of respiratory effort (21). The total recording
time was used as the denominator to calculate the
respiratory-disordered index (RDI) (6). The RDI was
calculated as the total number of respiratory events per
hour of record. The classification of OSA severity was
defined according to RDI as mild (5–14.9 events/h),
moderate (15–29.9 events/h), or severe ($30 events/h) (6).
In this study, we considered moderate to severe OSA
($15 events/h) as the cut-off for OSA.
Statistical analysis
Quantitative variables are expressed as means ¡ SD or
medians (interquartile ranges [IQRs]) or in percentages,
when appropriate. The Kolmogorov-Smirnov test was used
to assess the normal distribution of continuous variables.
The Students t-test for independent samples and the Mann-
Whitney U-test were used to compare continuous variables
when appropriate. The chi-squared test was used for
categorical variables. A univariate binary logistic regression
analysis was used to evaluate variables associated with the
presence of OSA, considering an RDI $15 events/h. The
tested variables were age ($45 years), BMI ($27 kg/m2),
neck circumference ($43 cm and $41 cm for males and
females, respectively) (22), waist circumference ($102 cm
and $88 cm for males and females, respectively) (23),
snoring, and a high risk for OSA, as assessed by the Berlin
questionnaire. The cut-offs used for age and BMI were
obtained using ROC curve analysis as the best values for
sensitivity and specificity. Variables with a p-value ,0.1
upon univariate analysis were entered into a multivariate
binary logistic regression. Because snoring was one of the
Berlin questionnaire domains, it was not included as an
independent variable. In addition, sensitivity, specificity,
and positive and negative predictive values of relevant
variables were also calculated. Data were analyzed with
SPSS 17.0 statistical software (SPSS Inc., Chicago, Illinois,
USA). A p-value #0.05 was considered significant.
Ethics
The institutional ethics committee approved this study
(SDC 3252/09/003), which was performed in accordance
with the Helsinki Declaration of 1975 (revised in 1983).
& RESULTS
We evaluated 90 HCM patients who were consecutively
recruited from the Cardiomyopathy Clinical Unit at a
tertiary University Hospital. None of the patients were
referred to the sleep laboratory because of sleep complaints
or had a previous diagnosis of OSA. Table 1 summarizes the
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patient demographics and the medications of the entire
population and divides the patients according to the
absence or presence of OSA. The vast majority of patients
were taking at least one cardiovascular medication (88%)
(Table 1). Consistent with recent studies of HCM patients,
moderate to severe OSA (Apnea-Hypopnea Index.
15 events/h) was extremely common and was present in
41% of our population (13–15). The OSA patients were
predominantly older males with higher BMIs, higher neck
and waist circumferences, and higher prevalences of AF
compared to the patients without OSA. However, in
contrast to the typical patient with OSA referred to the
sleep laboratory, the patients with HCM+OSA were not
particularly obese (Table 1).
The sleep characteristics and sleep-related questionnaires
of the entire population are summarized in Table 2
according to the presence or absence of OSA. A high OSA
risk, as evaluated by the Berlin questionnaire, was more
common among the patients with OSA than among the
patients without OSA (Table 2). The frequencies of positive
answers to the three categories of the Berlin questionnaire
(snoring, tiredness, and obesity) are also shown in Table 2.
Snoring and high BMI were more common in the OSA
patients. In contrast, tiredness did not differ significantly
among the patients with and without OSA. Moreover,
complaints of excessive daytime sleepiness, as assessed by
the Epworth Sleepiness Scale, were relatively low in the
entire population and were similar among patients with and
without OSA (Table 2).
We performed a binary logistic regression to evaluate the
predictors for OSA: the only variables that were indepen-
dently associated with OSA were age $45 years and the
presence of AF (Table 3). To translate our findings into
clinically meaningful data, we determined the sensitivity,
specificity, and positive and negative predictive values of
the main traits, including demographics and OSA-asso-
ciated complaints (Table 4). In general, all analyzed
variables performed poorly in the analysis, which highlights
the fact that several HCM patients are minimally sympto-
matic for OSA and do not have the typical features that
helps to identify OSA.
& DISCUSSION
In this study, the prevalence of OSA among consecutive
HCM patients was particularly high (41%), which aligned
with data from previous studies (13–15). Our study was
designed to determine the clinical characteristics that may
help to identify OSA among HCM patients. The main
Table 1 – General and clinical characteristics of the entire population of patients with hypertrophic cardiomyopathy and
the patients with and without obstructive sleep apnea.
Total population (n = 90) No OSA (n=53) OSA (n=37) p-value
Age, years 46¡15 41¡14 53¡13* ,0.001
Male, n (%) 46 (51) 26 (49) 21 (57) 0.742
Caucasians, n (%) 67 (74) 40 (75) 27 (72) 0.983
Body Mass Index, kg/m2 26.6¡4.9 25.3¡5.0 28.5¡4.0* 0.003
Neck, cm 37.4¡4.2 36.4¡3.2 39.0¡5.0* 0.002
Waist, cm 94.1¡12.1 91.0¡11.0 98.6¡11.7* 0.003
NYHA 2 and 3, n (%) 44 (49) 23 (43) 20 (54) 0.434
Atrial fibrillation, n (%) 18 (20) 5 (9) 13 (35)* 0.003
Antihypertensive, n (%)
Diuretics, n (%) 19 (23) 10 (20) 9 (27) 0.718
Beta-blockers, n (%) 61 (68) 34 (64) 26 (70) 0.705
Angiotensin-converting enzyme
inhibitor, n (%)
4 (5) 1 (2) 3 (8) 0.302
Calcium channel blockers, n (%) 18 (22) 9 (17) 10 (27) 0.375
Angiotensin receptor blocker, n (%) 14 (17) 7 (13) 7 (19) 0.660
Hypnotics, n (%) 5 (6) 2 (4) 3 (8) 0.398
Antidepressants, n (%) 13 (16) 6 (11) 7 (29) 0.481
Values are presented as percentages, means¡SD or medians (interquartile ranges) for the variables, as appropriate. OSA: obstructive sleep apnea.
*p#0.05.
Table 2 - Respiratory parameters derived from portable monitoring and sleep questionnaires for the entire population
and for patients with and without obstructive sleep apnea.
Total population (n= 90) No OSA (n=53) OSA (n =37) p-value
RDI, e/h 10.2 (4.5–24.8) 5 (2.7–8.1) 30.3 (21.2–39.3)* ,0.001
Lowest SpO2, % 84 (78–88) 87 (83–89.5) 80 (75.7–82.5)* ,0.001
Berlin high risk, n (%) 36 (40) 13 (25) 23 (66)* ,0.001
Snoring, n (%) 47 (52) 13 (35) 24 (65) 0.056
Tiredness, n (%) 35 (39) 18 (34) 19 (51) 0.152
BMI $30 kg/m2, n (%) 22 (24) 9 (16) 13 (35) 0.080
Epworth 7 (3–11) 7.5 (3.5–11) 7 (3–12.2) 0.924
Values are presented as percentages, means¡SD or medians (interquartile ranges) for the variables with skewed distribution. OSA: obstructive sleep
apnea. RDI: respiratory-disordered index; BMI: body mass index.
*p#0.05.
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findings were as follows: 1) the patients with HCM+OSA
did not complain of excessive daytime sleepiness; 2) the
patients with HCM+OSA were significantly older and had
higher BMI and neck and waist circumferences, but on
average, the patients with HCM+OSA were overweight and
typically not obese; 3) the Berlin questionnaire, which has
been previously validated to recognize patients with OSA in
other populations (18,24,25), was not useful in recognizing
OSA among HCM patients and 4) age $45 years and the
presence of AF were the only variables that were indepen-
dently associated with OSA. However, age $45 years had a
low sensitivity and specificity to predict OSA. Conversely,
the presence of AF presented a relatively high sensitivity
(0.72, 95% confidence interval [CI 95%], 0.46–0.89).
Altogether, our results suggest a lack of reliable clinical
predictors to identify OSA among HCM patients.
OSA is common in the general population (26,27) and is
independently associated with increased cardiovascular risk
(9,10). In HCM patients, evidence also shows that the
presence of OSA may be associated with worse structural
and functional impairment of the heart, including atrial and
aortic enlargement, worse New York Heart Association
functional class, and worse quality of life (13–15,28). In
HCM patients, AF is an independent marker of mortality
(29), and its prevalence is significantly higher (,5 times) in
the presence of OSA (13,14). Consistent with these previous
observations, in the present study, AF was ,3 to 4 times
more common among patients with HCM+OSA than in
patients with HCM but not OSA. Moreover, in the multi-
variate analysis, when all possible clinical predictors were
considered, only age and the presence of AF remained
statistically significant. These findings are worrisome and
indicate the necessity to test the hypothesis in future studies
that OSA may contribute to the genesis of heart remodeling
and AF among HCM patients. Despite this evidence, the
clinical suspicion of OSA among HCM patients remains
uncommon. There are several potential explanations for the
lack of OSA recognition among these patients. First,
cardiologists are not systematically trained in sleep medi-
cine. Second, because HCM is a genetic disease, it is often
diagnosed at young ages (when OSA is not frequent). Third,
HCM patients frequently do not exhibit the typical features
of OSA patients, such as obesity. Fourth, OSA has only
recently been shown to be extremely common in this
population. Finally, in contrast to the patient population
referred to the sleep laboratory (30), patients with
HCM+OSA frequently do not have typical clinical symp-
toms, such as tiredness and excessive daytime sleepiness.
The lack of excessive daytime sleepiness in patients with
OSA has also been observed in consecutive patients with
established cardiovascular disease, including hypertension
(24,25), metabolic syndrome (31), stroke (32), atrial fibrilla-
tion (33), and coronary artery disease (34). In our study,
regarding the sensitivity and specificity to predict OSA, the
Epworth Sleepiness Scale and Berlin questionnaire returned
low values for all of the tested variables; therefore, these
tools are not useful in clinical practice (Table 4). All of these
findings are important and emphasize that cardiologists
should take the responsibility to actively search for OSA
among patients with HCM.
Our study has some limitations that should be addressed.
First, because of the specific nature of the underlying disease,
the external validity of our data should be analyzed carefully.
Second, our sleep study was performed using a portable
monitor. However, portable monitors have also been
confirmed as a useful alternative to overnight polysomno-
graphy for the diagnosis of sleep-disordered breathing in a
series of patients with cardiovascular disease (34–36).
In conclusion, our study confirms that OSA is common in
HCM patients. In this population, using clinical character-
istics or validated questionnaires to identify OSA does not
accurately identify the patients at high risk for OSA. Our
results indicate the necessity for more accurate screening
strategies for identifying OSA in HCM patients.
Considering the high prevalence of OSA and its potential
cardiovascular consequences, sleep studies should be
widely considered for diagnosing OSA in patients with
HCM, particularly among elderly patients with AF.
Table 4 - Performance of clinical and sleep-related characteristics of the HCM patients.
Sensitivity (CI 95%) Specificity (CI 95%) PPV (CI 95%) NPV (CI 95%)
Age $45 years 0.26 (0.15–0.42) 0.42 (0.28–0.57) 0.31 (0.18–0.49) 0.36 (0.23–0.51)
Gender 0.38 (0.24–0.54) 0.54 (0.39–0.69) 0.44 (0.28–0.61) 0.48 (0.34–0.62)
BMI $27 kg/m2 0.53 (0.38–0.67) 0.69 (0.53–0.82) 0.65 (0.48–0.79) 0.57 (0.43–0.71)
BMI $30 kg/m2 0.59 (0.36–0.78) 0.63 (0.50–0.74) 0.34 (0.20–0.51) 0.82 (0.69–0.91)
Large neck 0.56 (0.34–0.76) 0.62 (0.50–0.73) 0.34 (0.20–0.51) 0.80 (0.67–0.90)
Large waist 0.50 (0.35–0.64) 0.67 (0.50–0.81) 0.65 (0.48–0.79) 0.51 (0.37–0.65)
AF 0.72 (0.46–0.89) 0.66 (0.54–0.72) 0.36 (0.21–0.53) 0.90 (0.77–0.96)
Snoring 0.56 (0.41–0.70) 0.77 (0.58–0.89) 0.79 (0.61–0.90) 0.53 (0.38–0.68)
Berlin 0.40 (0.25–0.57) 0.30 (0.18–0.44) 0.28 (0.17–0.43) 0.42 (0.26–0.59)
Epworth .10 0.46 (0.28–0.65) 0.60 (0.46–0.72) 0.36 (0.22–0.54) 0.69 (0.54–0.80)
PPV: positive predictive value; NPV: negative predictive value; AF: atrial fibrillation.
Table 3 - Binary logistic regression with the predictors of
obstructive sleep apnea among patients with
hypertrophic cardiomyopathy.
Univariate Multivariate
OR (CI 95%) p-value OR (CI 95%) p-value
Age $45 years 3.76 (1.55–9.13) 0.003 4.46 (1.47–13.54) 0.008
BMI $27 kg/m2 2.62 (1.10–6.24) 0.029 0.842 (0.25–2.88) 0.843
Large neck 2.18 (0.83–5.71) 0.067 2.48 (0.64–9.49) 0.185
Large waist 2.07 (0.87–4.92) 0.097 2.07 (0.67–6.43) 0.207
Atrial
fibrillation
5.20 (1.65–16.36) 0.005 5.37 (1.43–20.12) 0.013
Snoring 4.40 (1.59–12.18) 0.004
Berlin high risk 3.39 (1.41–8.18) 0.007 2.46 (0.83–7.28) 0.103
Constant 0.086 0.000
OR: odds ratio; CI: confidence interval; BMI: body mass index.
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